Morgan Stanley Immatics N.V. Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
A detailed history of Morgan Stanley transactions in Immatics N.V. stock. As of the latest transaction made, Morgan Stanley holds 2,804,092 shares of IMTX stock, worth $30.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,804,092
Previous 3,093,614
9.36%
Holding current value
$30.7 Million
Previous $14 Million
8.13%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding IMTX
# of Institutions
74Shares Held
93.6MCall Options Held
158KPut Options Held
0-
T. Rowe Price Investment Management, Inc. Baltimore, MD18.3MShares$201 Million0.06% of portfolio
-
Suvretta Capital Management, LLC New York, NY12MShares$132 Million2.23% of portfolio
-
Baker Bros. Advisors LP New York, NY10.2MShares$111 Million0.55% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$103 Million2.22% of portfolio
-
Rtw Investments, LP New York, NY6.97MShares$76.4 Million0.58% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $835M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...